| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1053: Cladribine for treating active relapsing forms of multiple sclerosis |
|
Medicine details |
|
| Medicine name | cladribine (Mavenclad®) |
| Formulation | Tablet |
| Reference number | 5306 |
| Indication | Treatment for active relapsing forms of multiple sclerosis |
| Company | Merck KGaA |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/03/2025 |
| NICE guidance | TA1053: Cladribine for treating active relapsing forms of multiple sclerosis |